Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 4Vitamin D Deficiency 2Triple Negative Breast Neoplasms 1Obesity 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colonic Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Bone Metabolism Biomarkers 1

Interventions

pembrolizumab 46Carboplatin 35Paclitaxel 28Specimen Handling 19Cyclophosphamide 17Capecitabine 16Magnetic Resonance Spectroscopy 15sacituzumab govitecan 13Gemcitabine 13Taxes 12Biopsy 12130-nm albumin-bound paclitaxel 11Albumin-Bound Paclitaxel 9olaparib 8Doxorubicin 8Nivolumab 7fludarabine 6Cisplatin 6eribulin 5atezolizumab 5Radiotherapy 5Docetaxel 5durvalumab 4Immunoglobulin G 4Fulvestrant 4Epirubicin 4Drug Therapy 4Bevacizumab 4veliparib 3toripalimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Cholecalciferol × 90 days × Clear all
NCT04677816 2026-04-14

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

Wake Forest University Health Sciences

Phase 2 Recruiting
50 enrolled
Breast

Vitamin D Deficiency, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡